Guidelines
Transition of Commissioning Policies
On 1st July 2022 NHS Cheshire and Merseyside Integrated Care Board (ICB) became the new statutory body responsible for ensuring health care services are available to meet the reasonable needs of the people of Cheshire & Merseyside.
Until such time as a single suite of commissioning policies can be developed and adopted, NHS Cheshire and Merseyside will continue to adopt and operate the CCG policies it has inherited at Place/borough level, which means that there will be no immediate change in commissioning policy for local people resident in those Places/boroughs from what was in place prior to 1st July 2022.
Documents
If a private consultation identifies a long-term condition or a need for medication which is available as routine NHS treatment, this should be provided as such by the patient's usual primary care prescriber if they are satisfied it is appropriate, and the private provider issues the first prescription.
The Pan Mersey Area Prescribing Committee recommends the sequential use of biological agents, adalimumab, bimekizumab, brodalumab, certolizumab, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab, in the management of psoriasis according to the attached flowchart.
The Pan Mersey Area Prescribing Committee recommends the sequential use of high cost agents, adalimumab, apremilast▼, certolizumab, etanercept, golimumab, infliximab, ixekizumab▼, secukinumab▼, tofacitinib▼ and ustekinumab in the management of psoriatic arthritis (PsA) in accordance with the recommendations below, and the accompanying Cheshire and Merseyside harmonised high cost drugs pathway.
High Cost Drugs Pathway for Psoriatic Arthritis